Trial · NCT03453840
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | AUC0-21d | Study day 0-day21 | Intensive PK participants only. Population PK participants are excluded here. | hr*ug/mL | GEOMETRIC_MEAN |
| PRIMARY | Recurrent Parasitemia Following Treatment by Day 42 (Recrudescence or New Infection) | up to study day 42 | All participants including intensive and population PK participants. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | AUC0-8h for Artemether | 0-8hr | Intensive PK participants only, so the participant number here is different from the numbers in the participant flow module, which includes both intensive and population PK participants. | hr*ng/mL | GEOMETRIC_MEAN |
| PRIMARY | AUC0-8h for Dihydroartemisinin | 0-8hr | Intensive PK participants only, so the participant number here is different from the numbers in the participant flow module, which includes both intensive and population PK participants. | hr.ng/mL | GEOMETRIC_MEAN |
| PRIMARY | Cmax for Lumefantrine | 0-21 days | ng/mL | GEOMETRIC_MEAN | |
| PRIMARY | Cmax for Artemether | 0-8hr | ng/mL | GEOMETRIC_MEAN | |
| PRIMARY | Cmax for Dihydroartemisinin | 0-8hr | ng/mL | GEOMETRIC_MEAN | |
| SECONDARY | Number of Participants With Serious Adverse Events | study day 0-42 | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Relationship Between Drug Resistance and Treatment Failure | study day 0-42 | |||
| OTHER_PRE_SPECIFIED | Metabolomic Measurements in HIV Infected vs HIV Uninfected Children | study day 0-42 | |||
| OTHER_PRE_SPECIFIED | Height-for-age (HFA) Associations With PK | study day 0 | |||
| OTHER_PRE_SPECIFIED | Diagnostic Sensitivity of LAMP, HS-RDT, and Microscopy for the Detection of Recurrent Parasitemia | study day 0-42 | |||
| OTHER_PRE_SPECIFIED | Weight-for-height (WFH) Associations With PK | study day 0 | |||
| OTHER_PRE_SPECIFIED | Weight-for-age (WFA) Associations With PK | study day 0 | |||
| OTHER_PRE_SPECIFIED | Prevalence of Gametocytemia | study day 0-42 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03453840/outcomes